Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

Summary

The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.

Interventions

• Gamma- Glutamylcysteine · DRUG

  400mg capsules once a day

• Gamma- Glutamylcysteine · DRUG

  400mg capsules orally (two times) per day

• Gamma- Glutamylcusteine · DRUG

  400mg capsules orally (three times) per day

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

1. Memory complaints;
2. MCI diagnosis
3. MoCA score between 18-25
4. Age 55 - 80 years old.
5. Ability to read and write in English

Exclusion Criteria:

1. Subjects with a history of cancer;
2. Subjects with a history of schizophrenia, manic-depressive disorder
3. Subjects on antioxidant therapy (ashwagandha, gingko biloba, N-acetylcysteine or glutathione)
4. Subjects on illicit drug (cocaine, heroin, marijuana, or fentanyl) abuse/dependence;

Sites (1)

• UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania · RECRUITING